Alnylam Pharmaceuticals | ALNY - Pre Tax Profit


Alnylam Pharmaceuticals reported $221.65M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Incyte USD 343.6M 46.34M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Moderna USD -799M 612M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 3.84B 1.33B Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR 2B 3.16B Mar/2026
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Takeda JPY -52.48B 186.34B Mar/2026
Tectonic Therapeutic USD -18.97M 63K Dec/2025
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026
Xencor USD -128.64M 124.37M Mar/2026